Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors

Author:

Grout John A.123ORCID,Sirven Philemon45ORCID,Leader Andrew M.123ORCID,Maskey Shrisha123ORCID,Hector Eglantine45ORCID,Puisieux Isabelle45ORCID,Steffan Fiona45ORCID,Cheng Evan123ORCID,Tung Navpreet123ORCID,Maurin Mathieu45ORCID,Vaineau Romain45ORCID,Karpf Lea123ORCID,Plaud Martin123ORCID,Begue Anne-Laure45ORCID,Ganesh Koushik45ORCID,Mesple Jérémy45ORCID,Casanova-Acebes Maria123ORCID,Tabachnikova Alexandra123ORCID,Keerthivasan Shilpa6ORCID,Lansky Alona123ORCID,Berichel Jessica Le123ORCID,Walker Laura17ORCID,Rahman Adeeb H.178ORCID,Gnjatic Sacha1279ORCID,Girard Nicolas1011ORCID,Lefevre Marine12ORCID,Damotte Diane13ORCID,Adam Julien14ORCID,Martin Jerome C.123ORCID,Wolf Andrea15ORCID,Flores Raja M.15ORCID,Beasley Mary Beth16ORCID,Pradhan Rachana17ORCID,Muller Soren17ORCID,Marron Thomas U.129ORCID,Turley Shannon J.6ORCID,Merad Miriam1237ORCID,Kenigsberg Ephraim18ORCID,Salmon Hélène12345ORCID

Affiliation:

1. 1The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

2. 2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

3. 3Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

4. 4Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, Paris, France.

5. 5PSL Research University, Paris, France.

6. 6Department of Cancer Immunology, Genentech, Inc., South San Francisco, California.

7. 7Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York.

8. 8Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.

9. 9Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.

10. 10Thorax Institute Curie Montsouris, Institut Curie, Paris, France.

11. 11UVSQ, Paris Saclay University, Versailles, France.

12. 12Department of Pathology, Institut Mutualiste Montsouris, Paris, France.

13. 13Department of Pathology, Assistance Publique–Hôpitaux de Paris, Paris Cité University, Paris, France.

14. 14Department of Pathology, Paris Saint-Joseph Hospital, Paris, France.

15. 15Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.

16. 16Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.

17. 17Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.

Abstract

Abstract It is currently accepted that cancer-associated fibroblasts (CAF) participate in T-cell exclusion from tumor nests. To unbiasedly test this, we used single-cell RNA sequencing coupled with multiplex imaging on a large cohort of lung tumors. We identified four main CAF populations, two of which are associated with T-cell exclusion: (i) MYH11+αSMA+ CAF, which are present in early-stage tumors and form a single cell layer lining cancer aggregates, and (ii) FAP+αSMA+ CAF, which appear in more advanced tumors and organize in patches within the stroma or in multiple layers around tumor nests. Both populations orchestrate a particular structural tissue organization through dense and aligned fiber deposition compared with T cell–permissive CAF. Yet they produce distinct matrix molecules, including collagen IV (MYH11+αSMA+ CAF) and collagen XI/XII (FAP+αSMA+ CAF). Hereby, we uncovered unique molecular programs of CAF driving T-cell marginalization, whose targeting should increase immunotherapy efficacy in patients bearing T cell–excluded tumors. Significance: The cellular and molecular programs driving T-cell marginalization in solid tumors remain unclear. Here, we describe two CAF populations associated with T-cell exclusion in human lung tumors. We demonstrate the importance of pairing molecular and spatial analysis of the tumor microenvironment, a prerequisite to developing new strategies targeting T cell–excluding CAF. See related commentary by Sherman, p. 2501. This article is highlighted in the In This Issue feature, p. 2483

Funder

National Institutes of Health

Fondation ARC pour la Recherche sur le Cancer

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3